Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck dB Geographic Context — Consolidated U.S. Revenue ($M) ($M)
Postgres DB segment_values (via lib/db.py)
Latest, FY2025
36,510
Period ended Dec 31, 2025
Change on a year earlier
+13.1%
32,277 in FY2024
History
15 years
Since FY2011
Sources
10
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | DB Geographic Context — Consolidated U.S. Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 36,510 | +13.1% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 32,277 | +13.3% | Form 10-K (filed 2025-02-25) ↗ |
| FY2023 | Dec 31, 2023 | 28,480 | +4.7% | Form 10-K (filed 2024-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 27,206 | +21.3% | Form 10-K (filed 2023-02-24) ↗ |
| FY2021 | Dec 31, 2021 | 22,425 | +14.5% | Form 10-K (filed 2022-02-25) ↗ |
| FY2020 | Dec 31, 2020 | 19,588 | +6.3% | Form 10-K (filed 2022-02-25) ↗ |
| FY2019 | Dec 31, 2019 | 18,420 | +1.1% | Form 10-K (filed 2022-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 18,228 | +4.6% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 17,424 | -5.5% | Form 10-K (filed 2020-02-26) ↗ |
| FY2016 | Dec 31, 2016 | 18,447 | +5.7% | Form 10-K (filed 2018-02-27) ↗ |
| FY2015 | Dec 31, 2015 | 17,451 | +2.2% | Form 10-K (filed 2018-02-27) ↗ |
| FY2014 | Dec 31, 2014 | 17,071 | -6.4% | Form 10-K (filed 2015-02-27) ↗ |
| FY2013 | Dec 31, 2013 | 18,246 | -10.5% | Form 10-K (filed 2014-02-27) ↗ |
| FY2012 | Dec 31, 2012 | 20,392 | -0.5% | Form 10-K (filed 2014-02-27) ↗ |
| FY2011 | Dec 31, 2011 | 20,495 | – | Form 10-K (filed 2014-02-27) ↗ |
Breakdown
What makes up db geographic context — consolidated u.s. revenue ($m)
- Consolidated EMEA Revenue ($M)14,580 · FY2025
- Consolidated China Revenue ($M)1,939 · FY2025
- Consolidated Japan Revenue ($M)2,711 · FY2025
- Consolidated Asia Pacific (ex-China & Japan) Revenue ($M)2,983 · FY2025
- Consolidated Latin America Revenue ($M)3,410 · FY2025
- Consolidated Other Countries Revenue ($M)2,878 · FY2025
- Consolidated Total International Revenue ($M)28,134 · FY2025
- Geographic Long-Lived Assets — United States ($M)15,021 · FY2025
- Geographic Long-Lived Assets — EMEA ($M)8,856 · FY2025
- Geographic Long-Lived Assets — China ($M)218 · FY2025
- Geographic Long-Lived Assets — Japan ($M)144 · FY2025
- Geographic Long-Lived Assets — Asia Pacific ($M)898 · FY2025
- Geographic Long-Lived Assets — Latin America ($M)128 · FY2025
- Geographic Long-Lived Assets — Other Countries ($M)51 · FY2025
Cite this data
StockData. (2026). Merck DB Geographic Context — Consolidated U.S. Revenue ($M) ($M), annual FY2011–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/db_geo_us_rev
See every metric in the Merck KPI table. Data updated Oct 26, 2026.